Table 2 Characteristics of Transplant Recipients With Influenza Infection.

From: T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients

 Patients (n = 31)
Infection
Influenza, n(%)
A/H1N12 (6.5)
A/H3N213 (41.9)
B16 (51.6)
Symptoms, n(%)
Fever19 (61.3)
Sore throat15 (48.4)
Cough30 (96.8)
Myalgia12 (38.7)
Dyspnea22 (71.0)
Headache14 (45.2)
Rhinorrhea19 (61.3)
Nausea or vomiting8 (25.8)
Diarrhea8 (25.8)
Fatigue5 (16.1)
Management
Oseltamivir, n (%)31 (100)
Median daily dose, mg (IQR)75 (60–150)
Median duration, days (IQR)5 (5–5)
Median time symptom onset and antivirals, days (IQR)6 (4–11)
Complications
Admission, n (%)28 (90.3)
Median duration admission, days (IQR)5 (2–10)
Pneumonia, n (%)12 (38.7)
Death at 6 months*, n (%)3 (9.7)
Rejection in the month prior or the 3 months after infection#, n (%)2 (6.5)
Influenza immunization, n (%)
Same season18/27 (66.7)
Previous season17/24 (70.8)
Laboratory results
Median creatinine clearance, mL/mn (IQR)54 (33–81)
Median leukocyte count, G/l (IQR)4.6 (4.0–6.3)
Median neutrophil count, G/l (IQR)3.6 (1.5–5.4)
Median lymphocyte count, G/l (IQR)0.7 (0.4–1.1)
  1. *Causes of death were: bleeding from fistula 3 months following influenza infection (n = 1), M.abscessus infection 4 months after influenza infection (n = 1) and chronic lung allograft dysfunction 4 months after influenza infection (n = 1)
  2. #Grade 1–2 rejection in the month preceeding influenza infection (n = 1), Grade 2 rejection 3 weeks following influenza infection (n = 1)
  3. IQR: interquartile range.